Linden Thomas Advisory Services’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.01M Sell
11,130
-63
-0.6% -$5.28K 0.08% 342
2026
Q1
$896K Sell
11,193
-323
-3% -$26.6K 0.09% 330
2025
Q4
$982K Sell
11,516
-130
-1% -$10.7K 0.1% 301
2025
Q3
$906K Buy
11,646
+246
+2% +$19.2K 0.09% 316
2025
Q2
$892K Buy
11,400
+186
+2% +$13.9K 0.1% 307
2025
Q1
$813K Buy
11,214
+849
+8% +$60.8K 0.11% 309
2024
Q4
$767K Buy
10,365
+221
+2% +$15.5K 0.1% 327
2024
Q3
$669K Buy
10,144
+558
+6% +$40.5K 0.09% 336
2024
Q2
$885K Buy
9,586
+1,873
+24% +$166K 0.14% 284
2024
Q1
$737K Buy
7,713
+698
+10% +$58.6K 0.12% 306
2023
Q4
$535K Buy
7,015
+527
+8% +$36.7K 0.1% 327
2023
Q3
$449K Sell
6,488
-7,960
-55% -$640K 0.1% 337
2023
Q2
$1.36M Buy
14,448
+687
+5% +$59.7K 0.3% 128
2023
Q1
$1.14M Buy
13,761
+475
+4% +$37.3K 0.28% 149
2022
Q4
$991K Buy
+13,286
New +$1.02M 0.28% 157

Other funds holding EW

Linden Thomas Advisory Services's EW Position: Q2 2026 in Review

Linden Thomas Advisory Services reduced its Edwards Lifesciences (EW) stake by 0.56% in Q2 2026, selling an estimated $5.28K and leaving 11,130 shares worth $1.01M. The position accounts for 0.08% of the portfolio, ranked #342.

Linden Thomas Advisory Services first reported a position in EW in Q4 2022 and has held it in 15 quarters since. The position peaked at $1.36M in Q2 2023. 374 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Linden Thomas Advisory Services held 11,130 shares of Edwards Lifesciences worth $1.01M as of Q2 2026.
  • Linden Thomas Advisory Services sold 63 Edwards Lifesciences shares in Q2 2026, an estimated $5.28K.
  • Edwards Lifesciences made up 0.08% of Linden Thomas Advisory Services's portfolio in Q2 2026, its #342 holding.
  • Linden Thomas Advisory Services first reported a position in Edwards Lifesciences in Q4 2022 and has held it in 15 quarters since.
  • Linden Thomas Advisory Services's Edwards Lifesciences position peaked at $1.36M in Q2 2023.
  • 374 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Linden Thomas Advisory Services's 13F filing for Q2 2026, filed 16 Jul 2026.